Class summary at a glance.

Every drug in the Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $177.3Mcombined across class
Total Rx claims: 5.1M2.6M unique beneficiaries
Generic mfrs (active): 13across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Valacyclovir

Brand: VALTREX · 5.1M Part D claims (CY24) · 2.6M beneficiaries · First FDA approval: 1995-08-01

9 generic mfrs 0 plans require PA

Low NADAC$0.230

→

Avg plan cost$1.47

Part D spend $171.9M 6× spread, current vs floor

Class share

97%

of class CY24 spend

View profile →

Penciclovir

Brand: Denavir · 9K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2018-09-24

4 generic mfrs 2 plans require PA

Low NADAC$64.73

→

Avg plan cost$82.71

Part D spend $5.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.